At present, the world has listed a variety of transdermal drug formulations of scopolamine, clonidine, nitroglycerin, fentanyl and so on. In recent years, new varieties are listed compound salicylic acid / triclosan patch, Zhou Xiao-estradiol transdermal patch and so on, a considerable portion of which has been in the domestic market.
According to a 16 cities in the domestic hospital market statistics, total sales in 2004 of fentanyl is about 33.332 million yuan, while sales of fentanyl patches is about 17.1285 million yuan, accounting for fentanyl market 51.39%; Xian-Janssen patch occupied the top spot market, the remaining market is the United States Alaz Corporation and Jiangsu Huarui partition. Not long ago, Shanxi reflex Pharmaceutical antihypertensive drugs clonidine transdermal patch available. And this variety in 2004 in the United States reached 260 million U.S. dollars in sales.
But the stark contrast, China’s current annual sales of transdermal formulations of drugs is only a rough estimate of about 1 billion yuan, compared with other formulations, its share of the market share is relatively small. In this regard, the view was expressed that the current size of the domestic market, the reason why transdermal preparation is relatively small, mainly due to technological level of domestic preparations restrictions. According to statistics, China’s current transdermal preparations have been made public yet the number of patents to 20, the number of published literature is not much.
Xi’an, 1000, and Pharmaceutical Chai Wenjing believes that the domestic processes in the transdermal patch indeed flawed, “for example viscosity, or on too strong, or would not.” Asia and the Shanxi Pharmaceutical Production Technology Division Po Ming-Jun Li believes that the domestic formulations technological level may not be the main factor, the real problem may come from the market level of acceptance. As the current domestic market, the prices of similar preparations of transdermal drug formulations is much higher than normal, so a limited degree of market acceptance, while the impact of clinical drug habits are also one of the factors.
Li Jun said that, in addition to chemical drugs transdermal preparations, and now the domestic market share of traditional Chinese medicine transdermal preparations are also considerable. But in fact, due to the complexity of medicine itself, and now the majority of Chinese medicines on the market, or transdermal formulations are traditional transdermal plasters, from the preparation process, quality control requirements, drug absorption rate and the modern transdermal delivery system gaps still exist. At the same time, this also for the development of this market has left a huge space. It is learned that far, foreign enterprises in the transdermal drug delivery technology in traditional Chinese medicine research.